New Jersey Awards Amneal Pharmaceuticals Tax Credits
The state is providing $60.56 million in tax credits to support the company’s pharmaceutical expansion in Piscataway.
Updated on Oct. 31, 2026 in Healthcare
Live Poll
Do you support state tax credits for private pharmaceutical companies to encourage local business expansion?
The New Jersey Economic Development Authority Board has approved $60.56 million in tax credits for Amneal Pharmaceuticals. This state-backed award supports a $240 million plan to expand manufacturing operations in Piscataway.
Why it matters
The investment aims to bolster domestic pharmaceutical production and enhance the reliability of the U.S. supply chain for complex medicines. This expansion is projected to create more than 330 new full-time jobs within the state.
The award covers a five-year period for the renovation of eight buildings. Amneal Pharmaceuticals produces over 300 types of medicine and supplies more than 160 million prescriptions annually.
The players
New Jersey Economic Development Authority
This state agency focuses on driving economic growth by providing financial incentives and support for businesses operating in New Jersey.
Amneal Pharmaceuticals
Headquartered in Bridgewater Township, this company is a major producer of generic, specialty, and biosimilar medicines.
The details
Amneal Pharmaceuticals will renovate eight buildings to create an integrated manufacturing campus in Piscataway. The project is supported by the Next New Jersey Manufacturing Program.
Timeline
Amneal Pharmaceuticals was founded in Paterson in 2002.
The expansion investment is planned over three years.
The tax credit award covers a period of five years.
Market Landscape
This project follows the pattern set by the Next New Jersey Manufacturing Program to incentivize local industrial growth. It positions the company to scale its production capacity domestically, contrasting with broader trends of offshoring pharmaceutical supply chains.
The expansion is expected to drive job growth in Piscataway, potentially benefiting local workers seeking full-time employment. For the broader public, the investment aims to increase the availability of generic and biosimilar medicines.
The takeaway
Amneal Pharmaceuticals is leveraging state incentives to consolidate its manufacturing footprint within New Jersey. This move reflects a wider strategy to secure supply chain stability by investing in integrated, multi-building campus facilities.
Further reading
Learn more about the local industry at New Jersey Healthcare.
Source note: This article includes information reported by WRNJ Radio.
Live Poll
Do you support state tax credits for private pharmaceutical companies to encourage local business expansion?
